Here is the latest American Chemical Society (ACS) Office of Public Affairs Weekly PressPac with news from ACS’ 34 peer-reviewed journals and Chemical & Engineering News.
This information is intended for your personal use in news gathering and reporting and should not be distributed to others. Anyone using advance ACS Office of Public Affairs Weekly PressPac information for stocks or securities dealing may be guilty of insider trading under the federal Securities Exchange Act of 1934.
Please cite the individual journal, or the American Chemical Society, as the source of this information.

Amid concerns about a pandemic of swine flu, researchers from Nebraska report for the first time that poultry carcasses infected with another threat — the “bird flu” virus — can remain infectious in municipal landfills for almost 2 years. Their report is scheduled for the June 15 issue of ACS’ semi-monthly journal Environmental Science & Technology.

Poultry carcasses infected with
bird flu can remain infectious
in municipal landfills for almost
two years, scientists report.
Credit: People’s Republic of China
(Click here to download a high
resolution version of this image)
Shannon L. Bartelt-Hunt and colleagues note that avian influenza, specifically the H5N1 strain, is an ongoing public health concern. Hundreds of millions of chickens and ducks infected with the virus have died or been culled from flocks worldwide in efforts to control the disease. More than 4 million poultry died or were culled in a 2002 outbreak in Virginia, and the carcasses were disposed of in municipal landfills. Until now, few studies have directly assessed the safety of landfill disposal.
“The objectives of this study were to assess the survival of avian influenza in landfill leachate and the influence of environmental factors,” says the report. The data showed that the virus survived in landfill leachate — liquid that drains or “leaches” from a landfill — for at least 30 days and up to 600 days. The two factors that most reduced influenza survival times were elevated temperature and acidic or alkaline pH. “Data obtained from this study indicate that landfilling is an appropriate method for disposal of carcasses infected with avian influenza,” says the study, noting that landfills are designed to hold material for much longer periods of time.

Scientists are reporting discovery of a potential new alternative to aspirin, ReoPro, and other anti-platelet agents used widely to prevent blood clots in coronary artery disease, heart attack and stroke. Their study, scheduled for the June 23 issue of ACS Nano, a monthly journal, involves particles of silver — 1/50,000th the diameter of a human hair — that are injected into the bloodstream.

Silver nanoparticles (shown) could
help prevent blood clots.
Credit: The American Chemical Society
(Click here to download a high
resolution version of this image)
Debabrata Dash and colleagues point out that patients urgently need new anti-thrombotic agents because traditionally prescribed medications too-often cause dangerous bleeding. At the same time, aging of the population, sedentary lifestyle and spiraling rates of certain diseases have increased the use of these drugs. Researchers are seeking treatments that more gently orchestrate activity of platelets, disk-shaped particles in the blood that form clots.
The scientists describe development and lab testing of silver nanoparticles that seem to keep platelets in an inactive state. Low levels of the nanosilver, injected into mice, reduced the ability of platelets to clump together by as much as 40 percent with no apparent harmful side effects. The nanoparticles “hold immense potential to be promoted as an antiplatelet agent,” the researchers note. “Nanosilver appears to possess dual significant properties critically helpful to the health of mankind — antibacterial and antiplatelet — which together can have unique utilities, for example in coronary stents.”

A technique that “silences,” or turns off, genes shows promise as a potential new treatment for liver fibrosis — the disease that leads to cirrhosis — scientists in Tennessee are reporting. Their study is scheduled for the June 1 issue of ACS’ Molecular Pharmaceutics, a bi-monthly journal. Cirrhosis is the 12th leading cause of death in the United States.
Ram Mahato and colleagues note that fibrosis involves build-up of scar tissue in the liver from chronic liver damage caused by hepatitis, alcohol abuse, toxins, or other factors. Advanced fibrosis can lead to cirrhosis, a condition in which the liver becomes so severely damaged that patients may require a transplant. There is no effective treatment, and patients urgently need new medications. Scientists believe one may emerge from the fascinating discovery that a protein called TGF-beta 1 triggers liver inflammation and that blocking the protein may help.
The researchers designed 10 chemically synthesized substances, termed siRNAs, with the ability to block or “silence” the TGF-beta 1 gene in the liver. When put into rat liver cells, the “gene silencers" decreased levels of type 1 collagen whose excessive production leads to fibrosis, as well as two other substances known to trigger liver inflammation, by almost 50 percent. The results suggest that gene silencing may be “an efficient and more specific approach for therapy of liver fibrosis,” the report states.

Scientists are reporting a potential solution to a problem that limits the human body’s ability to absorb and use medications for heart disease, Type-2 diabetes, cancer and other conditions. It is a “nano-hybrid microcapsule” that enables the stomach to absorb more of these so-called “poorly-soluble” medicines. Their study is scheduled for the June 1 issue of ACS’ Molecular Pharmaceutics, a bi-monthly journal.

Scientists report that new "microcapsules"
could help the stomach absorb certain
medicines.
Credit: The American Chemical Society
(Click here to download a high resolution
version of this image)
Finding ways to improve the stomach’s uptake of poorly soluble medicines has been one of the major challenges facing pharmaceutical companies. Estimates suggest, for instance, that 40 percent of potential new drugs fall into this category. In the new study, Clive Prestidge and colleagues note that one solution has been to include detergent-like substances in pills and capsules. However, that approach involves safety concerns, since the detergent can irritate the stomach lining, making it unsuitable for drugs that must be taken month after month.
The scientists describe development of a first-of-its-kind microcapsule made from lipid oils and nanoparticles 1/50,000th the width of a human hair. Although acting like conventional detergents, they seem unlikely to irritate the stomach. In test tube experiments, microcapsule versions of the arthritis drug, indomethacin, dissolved up to five times faster than a regular version of the drug. Lab rats given the new microcapsule version absorbed almost twice as much of the drug.

Food manufacturers are searching for new ways to reduce the amount of salt added to products ranging from potato chips to salad dressings while preserving the salty taste that consumers crave, according to an article scheduled for the June 1 issue of Chemical & Engineering News, ACS’ weekly newsmagazine.
C&EN assistant editor Carmen Drahl notes in the article that researchers have been working toward that goal for years, as consumers concerned about high blood pressure sought to limit salt intake on the advice of public health officials. But finding a replacement for salt, or sodium chloride, is no simple task. One of the problems researchers face is lack of a detailed understanding of the basic biology of salty taste. But new pieces of the puzzle are emerging, including the discovery last year of what some scientists claim is the primary receptor responsible for human salt taste perception.
Despite this challenge, companies are forging ahead with salt reduction research. One of the most widely used salt replacers, potassium chloride, resembles salt in terms of cooking performance but has a bitter taste that some consumers find unpleasant. Several companies are developing additives to mask this bitterness. Other approaches include developing smaller salt particles so that the tongue perceives their taste more quickly. Other researchers are exploring oil-based salt emulsions that provide an enhanced perception of saltiness while using less salt. No one strategy seems to work for every food and beverage, the article notes, but help is on the way.
The American Chemical Society’s Office of Public Affairs (OPA) has created a new pressroom blog to highlight prominent research from ACS’ 34 journals. The blog includes daily commentary on the latest news from the weekly PressPac, including video and audio segments from researchers on topics covering chemistry and related sciences, including nanotechnology, food science, materials science and the environment. The pressroom blog will also cover updates on ACS’ awards, the national meetings and other general news from the world’s largest scientific society.
General science press releases on a variety of chemistry-related topics.
More ACS News
PressPac information is intended for your personal use in news gathering and reporting and should not be distributed to others. Anyone using advance PressPac information for stocks or securities dealing may be guilty of insider trading under the federal Securities Exchange Act of 1934.
The American Chemical Society — the world’s largest scientific society — is a nonprofit organization chartered by the U.S. Congress and a global leader in providing access to chemistry-related research through its multiple databases, peer-reviewed journals and scientific conferences. Its main offices are in Washington, D.C., and Columbus, Ohio.